Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
5.85
+0.22 (3.91%)
At close: Feb 18, 2026, 4:00 PM EST
5.73
-0.12 (-2.02%)
After-hours: Feb 18, 2026, 5:33 PM EST
Candel Therapeutics Employees
Candel Therapeutics had 38 employees as of December 31, 2024. The number of employees decreased by 4 or -9.52% compared to the previous year.
Employees
38
Change (1Y)
-4
Growth (1Y)
-9.52%
Revenue / Employee
n/a
Profits / Employee
-$598,921
Market Cap
321.16M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 38 | -4 | -9.52% |
| Dec 31, 2023 | 42 | -34 | -44.74% |
| Dec 31, 2022 | 76 | 11 | 16.92% |
| Dec 31, 2021 | 65 | 24 | 58.54% |
| Mar 31, 2021 | 50 | - | - |
| Dec 31, 2020 | 41 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AC Immune | 172 |
| Century Therapeutics | 150 |
| X4 Pharmaceuticals | 143 |
| Foghorn Therapeutics | 112 |
| Armata Pharmaceuticals | 60 |
| Atea Pharmaceuticals | 56 |
| Immuneering | 54 |
| Cybin | 50 |
CADL News
- 7 days ago - Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit - GlobeNewsWire
- 16 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 - GlobeNewsWire
- 3 months ago - Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 3 months ago - Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors - GlobeNewsWire
- 3 months ago - Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 4 months ago - Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board - GlobeNewsWire
- 4 months ago - Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. - GlobeNewsWire